- Home
- KMPR vs JANX Comparison
KMPR vs JANX Comparison
Compare KMPR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMPR
- JANX
- Stock Information
- Founded
- KMPR 1990
- JANX 2017
- Country
- KMPR United States
- JANX United States
- Employees
- KMPR N/A
- JANX N/A
- Industry
- KMPR Property-Casualty Insurers
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- KMPR Finance
- JANX Health Care
- Exchange
- KMPR Nasdaq
- JANX Nasdaq
- Market Cap
- KMPR 2.2B
- JANX 1.8B
- IPO Year
- KMPR N/A
- JANX 2021
- Fundamental
- Price
- KMPR $40.79
- JANX $34.11
- Analyst Decision
- KMPR Hold
- JANX Buy
- Analyst Count
- KMPR 3
- JANX 11
- Target Price
- KMPR $56.67
- JANX $77.40
- AVG Volume (30 Days)
- KMPR 1.2M
- JANX 1.1M
- Earning Date
- KMPR 11-05-2025
- JANX 11-06-2025
- Dividend Yield
- KMPR 3.14%
- JANX N/A
- EPS Growth
- KMPR N/A
- JANX N/A
- EPS
- KMPR 3.89
- JANX N/A
- Revenue
- KMPR $4,845,500,000.00
- JANX $10,000,000.00
- Revenue This Year
- KMPR $0.77
- JANX N/A
- Revenue Next Year
- KMPR $6.74
- JANX $89.91
- P/E Ratio
- KMPR $10.50
- JANX N/A
- Revenue Growth
- KMPR 4.45
- JANX N/A
- 52 Week Low
- KMPR $33.91
- JANX $21.73
- 52 Week High
- KMPR $73.01
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- KMPR 47.42
- JANX 70.73
- Support Level
- KMPR $36.12
- JANX $28.25
- Resistance Level
- KMPR $38.84
- JANX $30.23
- Average True Range (ATR)
- KMPR 1.41
- JANX 2.12
- MACD
- KMPR 0.59
- JANX 0.39
- Stochastic Oscillator
- KMPR 95.66
- JANX 97.64
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.